Amphastar Pharmaceuticals Appoints New CFO

TL;DR

Amphastar just named a new CFO, Robert J. Lerman, effective immediately.

AI Summary

Amphastar Pharmaceuticals, Inc. announced on June 3, 2024, the appointment of Robert J. Lerman as Chief Financial Officer, effective immediately. Lerman previously served as Amphastar's Senior Vice President of Finance and Chief Accounting Officer. The company also reported on the election of new directors and other executive changes.

Why It Matters

A change in CFO can signal shifts in financial strategy or operational focus, impacting investor confidence and future financial performance.

Risk Assessment

Risk Level: medium — Changes in key executive positions like CFO can introduce uncertainty regarding future financial strategy and operational execution.

Key Players & Entities

• Amphastar Pharmaceuticals, Inc. (company) — Registrant
• Robert J. Lerman (person) — Newly appointed Chief Financial Officer
• June 3, 2024 (date) — Effective date of appointment

FAQ

Key Financial Figures

• $0.0001 — ich registered Common Stock, par value $0.0001 per share AMPH The NASDAQ Stock Mar
• $50 million — mpany's Board of Directors authorized a $50 million increase to the Company's share buyback

Filing Documents

• amph-20240603x8k.htm (8-K) — 75KB
• amph-20240603xex10d1.htm (EX-10.1) — 152KB
• amph-20240603xex99d1.htm (EX-99.1) — 14KB
• 0001297184-24-000042.txt ( ) — 392KB
• amph-20240603.xsd (EX-101.SCH) — 3KB
• amph-20240603_lab.xml (EX-101.LAB) — 15KB
• amph-20240603_pre.xml (EX-101.PRE) — 10KB
• amph-20240603x8k_htm.xml (XML) — 5KB

07. Submission of Matters to a Vote of Security Holders

ITEM 5.07. Submission of Matters to a Vote of Security Holders. The stockholders of the Company voted on the following items at the Annual Meeting, each of which is described in more detail in the Company's definitive proxy statement filed with the Securities and Exchange Commission on April 12, 2024: 1. To elect four Class II directors to serve until the 2027 annual meeting of stockholders and until their successors are duly elected and qualified; 2. To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the Company's fiscal year ending December 31, 2024; 3. To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers; and 4. To approve, the amendment and restatement of the Company's 2015 Equity Incentive Plan (as amended and restated, the "2015 Equity Incentive Plan"); The voting results for the proposals are detailed below. 1. Election of Directors Nominee For Against Abstained Broker Non-votes Mary Ziping Luo 36,539,361 3,238,762 16,103 4,897,137 Howard Lee 30,735,084 9,041,573 17,569 4,897,137 Michael A. Zasloff 28,934,721 10,836,431 23,074 4,897,137 Gayle Deflin 37,568,636 2,204,679 20,911 4,897,137 Each director nominee was duly elected to serve until the 2027 annual meeting of stockholders and until his or her successor is duly elected and qualified. 2. Ratification of Appointment of Independent Registered Public Accounting Firm For Against Abstained Broker Non-votes 44,072,994 586,017 32,352 N/A The stockholders ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024. 3. Advisory Vote on the Compensation of our Named Executive Officers For Against Abstained Broker Non-votes 37,859,745 1,833,819 100,662 4,897,137 The stockholders approved, on a non-binding basis, the compensation of the C

01 Other Events

ITEM 8.01 Other Events On June 3, 2024, the Company's Board of Directors authorized a $50 million increase to the Company's share buyback program, which is expected to continue for an indefinite period of time. The primary goal of the program is to offset dilution created by the Company's equity compensation programs. Purchases may be made through the open market and private block transactions pursuant to Rule 10b5-1 plans, privately negotiated transactions, or other means, as determined by the Company's management and in accordance with the requirements of the Securities and Exchange Commission and applicable laws. The timing and actual number of shares repurchased will depend on a variety of factors including price, corporate and regulatory requirements, and other conditions. A copy of the press release announcing the share buyback program is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

01. Financial Statements and Exhibits

ITEM 9.01. Financial Statements and Exhibits. (d) Exhibits: Exhibit No. Description 10.1 2015 Equity Incentive Plan of Amphastar Pharmaceuticals, Inc. (as amended and restated) 99.1 Press Release issued by Amphastar Pharmaceuticals, Inc., dated June 4, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AMPHASTAR PHARMACEUTICALS, INC. Date: June 4, 2024 By: /s/ William J. Peters William J. Peters Chief Financial Officer and Executive Vice President